Karyopharm and Antengene sign exclusive developmemnt and license agreement
Karyopharm and Antengene Corp. announced their entry into an exclusive license agreement for development and commercialization of four of Karyopharm’s novel, oral drug candidates, including selinexor, eltanexor, verdinexor, and KPT-9274. May 24, 2018